713 related articles for article (PubMed ID: 21349409)
41. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors.
Turaga KK; Kvols LK
CA Cancer J Clin; 2011; 61(2):113-32. PubMed ID: 21388967
[TBL] [Abstract][Full Text] [Related]
42. Gastroenteropancreatic neuroendocrine tumors. Where are we now?
Castellano D
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():1. PubMed ID: 21365184
[No Abstract] [Full Text] [Related]
43. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
44. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract][Full Text] [Related]
45. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
46. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
47. A report card on outcomes for surgically treated gastrointestinal cancers: are we improving?
O'connell JB; Maggard MA; Liu JH; Etzioni DA; Ko CY
J Surg Res; 2004 Oct; 121(2):214-21. PubMed ID: 15501461
[TBL] [Abstract][Full Text] [Related]
48. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Fraenkel M; Kim MK; Faggiano A; Valk GD
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
[TBL] [Abstract][Full Text] [Related]
49. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States.
Lau MK; Davila JA; Shaib YH
Pancreas; 2010 May; 39(4):458-62. PubMed ID: 19924019
[TBL] [Abstract][Full Text] [Related]
50. A retrospective clinico-pathological analysis of neuroendocrine tumors of the gastrointestinal tract.
Amarapurkar DN; Juneja MP; Patel ND; Amarapurkar AD; Amarapurkar PD
Trop Gastroenterol; 2010; 31(2):101-4. PubMed ID: 20862983
[TBL] [Abstract][Full Text] [Related]
51. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
[TBL] [Abstract][Full Text] [Related]
52. Pediatric intestinal foregut and small bowel solid tumors: a review of 105 cases.
Zhuge Y; Cheung MC; Yang R; Eldick D; Koniaris LG; Sola JE
J Surg Res; 2009 Sep; 156(1):95-102. PubMed ID: 19560163
[TBL] [Abstract][Full Text] [Related]
53. [Clinical significance of new classification of gastroenteropancreatic neuroendocrine neoplasms].
Zhu XZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):12-4. PubMed ID: 23691561
[TBL] [Abstract][Full Text] [Related]
54. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
[TBL] [Abstract][Full Text] [Related]
55. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies.
Halfdanarson TR; Strosberg JR
Curr Clin Pharmacol; 2015; 10(4):305-10. PubMed ID: 26548907
[TBL] [Abstract][Full Text] [Related]
56. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
[TBL] [Abstract][Full Text] [Related]
57. Foreword: Gastroenteropancreatic system and its tumors: Part 2.
LeRoith D
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):xiii-xv. PubMed ID: 21349407
[No Abstract] [Full Text] [Related]
58. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
59. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.
Lombard-Bohas C; Mitry E; O'Toole D; Louvet C; Pillon D; Cadiot G; Borson-Chazot F; Aparicio T; Ducreux M; Lecomte T; Etienne PL; Cacheux W; Legoux JL; Seitz JF; Ruszniewski P; Chayvialle JA; Rougier P;
Neuroendocrinology; 2009; 89(2):217-22. PubMed ID: 18719344
[TBL] [Abstract][Full Text] [Related]
60. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
